Each month, Research!America features a member in its award-winning newsletter The Research Advocate. Among those recently spotlighted in Members Take Action:
In 1997, a year after the gene that causes Friedreich's ataxia was identified, Ron and Raychel Bartek received the diagnosis of their son, Keith, and discovered that there was no treatment for the disease and no group dedicated to finding one. So they started FARA. Since then, FARA alone has funded more than $20 million in research on the disease and helped secure a similar amount from co-funding organizations. That has helped lead to multiple clinical trials encompassing a range of treatment approaches.
FARA President Ron Bartek remembers when he and his wife decided to start a nonprofit dedicated to finding a treatment for Friedreich's ataxia.
"On the night we received Keith's diagnosis, we saw online there was no treatment, very little research into the disease and no organization devoted entirely to supporting such research. We were living in the DC suburbs, we were 30 minutes from the [National Institutes of Health], and we both worked on Capitol Hill," he recalled. "Maybe we're supposed to do this."
Things moved quickly after that: On the day FARA was approved for incorporation, Bartek drove to the NIH to apply for a workshop grant. A friend helped them quickly attain 501(c)(3) status; with that secured, the NIH approved the workshop grant. Two months later, FARA co-hosted with the National Institute of Neurological Disorders and Stroke the world's first Friedreich's ataxia workshop. Sixty-five scientists from around the world joined 15 NINDS researchers for that first conference.
Though a treatment remains elusive, that's about the only thing that hasn't changed. The last conference on Friedreich's ataxia was held in Strasbourg, France; 200 people attended, and many others were turned away due to space limitations. Pharmaceutical companies and advocacy organizations were well-represented. The Barteks' initial goal was being accomplished.
"That was our first objective: to grow the field," Bartek said.
Most importantly, an approved treatment may be near at hand—with others following along and providing a "cocktail therapy" to treat the disease effectively and eliminate it in subsequent generations.
Research!America's obvious effectiveness at advocacy is a critical reason why FARA is a member.
"Research!America is a key advocacy organization in support of medical and health research across the front. They're so effective at the highest levels and in collaborating with other advocates," Bartek said. "With all of us pulling together, we're such a powerful voice."
When the Pancreatic Cancer Action Network was founded in 1999, the 5-year relative survival rate was 5.3%, according to National Cancer Institute statistics. In the intervening years, the survival rate has remained stubbornly low. What is different is awareness: Today, more research is being conducted by more scientists, and the pancreatic cancer advocacy community has never been bigger. So too for Manhattan Beach, CA-based Pancreatic Cancer Action Network, which hired its first employee in 2000 and will soon hire its 100th.
President and CEO Julie Fleshman, JD—who was that first employee—can explain just how far the science around pancreatic cancer has come. Tumors tend to be surrounded by, in Fleshman's words, a dense microenvironment that makes drug delivery difficult; it's one of many reasons why treating pancreatic cancer is so challenging.
"That finding ... is something we've only started to appreciate the significance of in the last five years," Fleshman, who lost her father to pancreatic cancer in 1999, said. "It shows you that when you finally dedicate time and resources and people to a topic, you start to understand what the challenges are, which then allows people to focus their efforts in the right way to make scientific advancements."
And the Pancreatic Cancer Action Network sees those advances are coming. Early in 2011, the organization announced an initiative to double the survival by 2020; now, seven years out, Fleshman said reaching the goal will be difficult but far from impossible. Even so, the future holds promise for patients. There are 142 active clinical trials, according to the organization's comprehensive pancreatic cancer clinical trials database. Moreover, earlier-stage research is ongoing and being taken up by an ever greater number of scientists.
"That's probably the most significant change," Fleshman said. "We're learning more about the disease, we're understanding better the challenges about why it is so difficult to treat, and that is going to get us to changing patient outcomes in the future."
And because research is such a critical part of the puzzle, Fleshman said it's important for the organization to be a Research!America member.
"Biomedical research is a key priority for our organization," she said. "With pancreatic cancer, there is no detection tool, and we need better treatment options. We're not going to make those scientific advances unless there is more federal funding for the disease. We're very proud to partner with Research!America to make medical research a national priority."
Founded in 2002, the Association of Clinical Research Organizations-ACRO-began with five institutional members and currently has eight, all of which are in the private sector; those eight companies are far and away the giants of the industry. Though academic and nonprofit organizations are not prohibited from becoming ACRO members, ACRO is focused on the private sector.
ACRO began as a trade organization designed to promote and represent clinical research organizations; little more than a decade later, ACRO is much more involved in advocacy and legislative and regulatory affairs. And it's not just American regulatory affairs; the group keeps abreast of developments in Europe and emerging markets, like India, wherever its members do business.
"We're being a little more proactive," said John Lewis, ACRO's vice president for public affairs, "having started out playing defense primarily."
Though ACRO's website lists a number of key issue areas, the most pressing domestic issue over the past several years has been taxation. One particular concern was tax repatriation legislation, since ACRO's members are mostly U.S.-based but roughly half of their revenues come from outside the U.S., Lewis said. ACRO's members are also engaged with certain tenets of the R&D tax credit.
"In other countries-the U.K., France, Canada, Austria, a number of other countries-CROs can claim an R&D tax credit," Lewis said. "... And there are many factors, but we think that's one of the factors why more research is being done outside the United States."
According to clinicaltrials.gov, as recently as 2008, about 53% of industry-sponsored clinical trials were conducted in the United States. That percentage dropped to about 47% in 2012.
Being a member of a respected organization like Research!America enables ACRO to leverage its public policy messaging around the promotion of medical research. Membership also opens up opportunities to participate in Research!America's polls, such as the recent one on public attitudes toward clinical trials.
"By being able to partner with Research!America on the clinical trials poll, we could draw a broader audience for our core issue. We subsequently shot videos with Mary Woolley, which added great content for our YouTube channel, and we are now discussing a Hill briefing on clinical trial participation," Lewis said. "So, from ACRO's perspective, we were able to co-sponsor important research, boost our communications activities and take our message to Congress. This is a great ‘return on investment' from our membership."
From the beginning, the American Chemical Society has had a tie to medicine: It was founded in 1876 by 35 chemists at the College of Pharmacy of the City of New York. Chemistry in the pursuit of health remains a focus for ACS and its membership-now more than 163,000. The organization employs nearly 2,000 people; most work to produce the organization's more than 40 peer-reviewed journals and multiple databases that are indispensable to scientists worldwide.
On August 25, 1937, President Franklin D. Roosevelt signed the law that gave ACS its congressional charter. Its mandates included the promotion of research and advancement of the science; maintenance of standards of ethics and education; increase and diffusion of chemical knowledge; and promotion of the science in the interest of public happiness and welfare, education and economic development.
This language, from a 76-year old public law, may seem dusty. Instead, it is dynamic: Madeleine Jacobs, ACS executive director and CEO, refers to the charter each time she meets a new employee.
"It guides us in everything we do," Jacobs said. "We're very proud to be one of the few organizations to have it and, believe me, I cite this all the time."
Another guiding principle is ACS' tagline, "Chemistry for life," which intentionally incorporates the facet of medical research. Chemistry is the basis for pharmaceuticals, after all, and Jacobs said ACS has 40,000 industrial and academic members involved in the life sciences in some way. She added that many ACS members receive funding from the National Institutes of Health. "It's a big source of funding for a large number of our academic members," she said.
Jacobs explained that ACS advocates for a "vital, robust and sustained" scientific enterprise. Other prongs of its advocacy include a favorable environment for industry and entrepreneurs as well as a workforce that is well-educated in the STEM fields.
Those are also tenets of Research!America's advocacy, and that alignment is a key reason why ACS is a member of Research!America's alliance.
"I don't think that we can be successful working in a vacuum, working individually. I think we can be much more successful when we work together," Jacobs said. "[Research!America is] the kind of coalition we want to be involved in ... Whatever we can bring to the table in helping you achieve, I think it also means we will be achieving things for our members as well."
Since 1974, AdvaMed-short for Advanced Medical Technology Association-has represented the medical technology sector. Today, the organization has more than 300 members of all sizes, representing medical devices, diagnostic products and health information systems.
The idea of a medical device may conjure images of a cutting-edge machine using breakthrough technology or perhaps the latest diagnostics or genetics test; indeed, that would certainly qualify. But items such as tongue depressors and hospital gowns also fall under the umbrella of AdvaMed's membership.
"In a sort of broad-brush way, it's everything that's used in medicine that's not a drug," explains David Nexon, AdvaMed's senior executive vice president.
The medical device tax that was enacted with the Affordable Care Act is a key policy concern for AdvaMed at the moment. "It's such a drain on our U.S. competitiveness and our companies' ability to fund research and development," Nexon said.
Other policy concerns include keeping America's taxes competitive globally as part of any tax reform movement; changing the incentives in the reimbursement system to focus on sustaining medical progress while reducing costs; helping AdvaMed's members navigate the regulatory and payment structures outside the U.S.; and continually working with the Food and Drug Administration to improve the agency's efficiency at reviewing new technology. Like pharmaceutical companies, medical device companies pay user fees to FDA in order to speed up the approval process; sequestration has affected FDA's ability to use those fees for their intended purposes.
"The sequester, with the way it's set up, it keeps you paying the user fees but then doesn't let FDA use a portion of the money," Nexon said, "and that's clearly wrong."
Nexon said that Research!America's focus on advocating for all research, with the eventual end goal of better treatments for patients, is a key reason why AdvaMed is a member.
"I think Research!America is a very powerful voice for the importance of both public investment in research, but also creating a climate in the United States that's friendly to medical progress and developing innovation, whether that comes out of the private sector or the public sector," Nexon said.
To learn more, visit http://advamed.org.
The genesis of the Parkinson's Action Network (PAN) goes back to 1987, four years before the organization's founding. That year, Joan Samuelson left a career in law after being diagnosed with Parkinson's disease; she threw her might into advocating for people living with Parkinson's. Four years later, PAN was born, and its advocacy continues today.
PAN is a unique organization in the patient advocacy world; it represents the entire Parkinson's community on funding and quality of life policy priorities for those living with the disease. PAN works with other national Parkinson's organizations and is the only organization addressing government programs and policies that impact the community.
"We've worked on a vision that if our community came together on policy issues, with one, singular voice, we would be much more effective," said PAN CEO Amy Comstock Rick, JD, who became a Research!America Board member in March. "Really in the last 10 years, we've been able to effectively achieve that mission so that PAN is the only organization in the Parkinson's community that works on policy issues, even though we have a number of national organizations."
Augmenting its policy expertise is PAN's robust grassroots network, with directors and assistant directors at the state level and volunteers in key congressional districts. But, Rick points out, PAN does not maintain its own chapters; rather, consistent with its goal of unification, it relies on the chapter structures of the other national organizations to reach the community.
"PAN does advocacy work through our grassroots leaders," Rick said. "... Without these advocates, the Parkinson's community couldn't accomplish all of the work we do each year. These advocates are the core of PAN."
The chance to network beyond the community and beyond Washington are key reasons for PAN's membership with Research!America.
"Our structure is so unique ... the goals of Research!America are really the same goals in terms of a unified voice. Research!America gives us not only the opportunity to work with other disease organizations," Rick said, "it also is a great way for us to work with other members of the community who have the same ultimate goal, which is getting therapies out there ... You have to get to know people and see things from their perspective, and having an organization like Research!America that brings us together really adds value to that."
In 1976, Ken Stuart, PhD, opened the Issaquah Group for Health and Environmental Research, which was set up to foster the best and brightest researchers who were working to combat trypanosomes and related parasitic diseases. Today, the organization is known as Seattle BioMed, and it employs 15 faculty members and more than 330 workers in all.
Despite its expansion over the past 37 years, current President Alan Aderem, PhD, explains that Seattle BioMed (officially known as Seattle Biomedical Research Institute) has stayed true to its roots. The organization's focus lies in the basic research that leads to better understanding of, and interventions for, tuberculosis, malaria, HIV and parasites such as those causing African sleeping sickness-diseases that, at a fundamental level, remain a mystery.
Aderem was one of three co-founders of the Institute for Systems Biology, also a Research!America member. Aderem believes that systems biology, when integrated with immunology and infectious disease research, can accelerate progress in the development of vaccines, drugs and diagnostics, and he is implementing that approach at Seattle BioMed. There's already one success story.
"We have a program in South Africa with 6,000 adolescents all latently infected with TB. We took blood from them every six months over the course of two years. In that time, a small number of them became ill with active TB," Aderem explained. "By comparing the networks within the wide-circulating white blood cells, we were able to come up with a predictive network that allows us to tell very early on whether or not a kid with a latent infection is likely to get sick."
Aderem said that combating public health threats such as TB is critically important to the U.S.
"Totally drug resistant TB is a very real danger. This is especially true because TB is so easy to spread worldwide," Aderem said. "We need to make lawmakers aware of this issue because it's a major public health threat-not only in resource-poor countries, but also in the United States. Despite the fact that the bacterium that causes tuberculosis was discovered 130 years ago, we still don't have an effective vaccine against it. We need to understand the basic mechanisms by which the bacterium subverts the immune system. Continued investment in scientific research is critical, and the advocacy and public polling carried out by Research!America helps bring these issues to lawmakers' attention for the collective of medical research institutes that includes Seattle BioMed."
Learn more at www.seattlebiomed.org.
From its original 121 member institutions when it was founded in 1969, AACN has grown to more than 700 member institutions in all 50 states, DC and Puerto Rico. Besides advocacy, AACN is a resource to its members in a number of other ways: sponsoring an autonomous accreditation unit, developing curriculum standards and warehousing statistics about nursing schools and students across the country.
AACN's CEO, Geraldine "Polly" Bednash, PhD, RN, came to AACN in 1986; she explains the organization's growth like this: "When I first started at AACN, we had seven staff members, and this organization was basically a networking group for deans of nursing programs," she said. "Now, however, AACN has nearly 50 employees and strives to benefit everyone involved in nursing academics-deans, faculty, students, grad students, researchers and business staff."
As a profession, nursing has expanded similarly. Besides the traditional roles of nurses as frontline caregivers, nurses can now be found as CEOs and high-level government appointees. (Bednash points out that Marilyn Tavenner, acting administrator of the Centers for Medicare & Medicaid Services, began her career as a nurse.)
"We've become a much more expansive career option, with lots of places where nursing knowledge and experience and science is important to the decisions shaping both the delivery and the business of health care," Bednash said.
Advocacy is another key facet of AACN's work. Nurses can play a key role in explaining the implications of research to legislators and the need to follow the evidence when making health care policy. To that end, AACN has extensive resources for nurse scientists and nursing researchers to understand and explain why its work is important.
Research!America's own work in that area is a key reason why AACN is a member.
"AACN applauds Research!America for delivering the message that science is an important part of this country's investment for the future, and that the National Institutes of Health is a vital resource for improving the health care of our nation's population," Bednash said. "Research!America is making clear that research is not some esoteric, distant activity created by people in obscure places, but in fact is critically important to addressing this country's major health care concerns."
Learn more at www.aacn.nche.edu.
The Georgia Research Alliance doesn't conduct research itself; instead, as its name implies, it facilitates research collaboration among six universities in the State of Georgia: Clark Atlanta University, Emory University, the Georgia Institute of Technology, Georgia State University, Georgia Health Sciences University and the University of Georgia. Since 1990, GRA has leveraged $525 million of state funding into $2.6 billion in additional public and private financing; moreover, it has played a role in the creation of more than 150 companies.
As President and CEO C. Michael Cassidy explains it, GRA at its heart is an economic development organization. It achieves its goal of growing the state's economy by first recruiting world-class scientists and building R&D capacity and, later, shaping and seeding companies around the most promising discoveries. GRA is planning to scale up the latter in the near future, but not at the expense of the former.
"We have an overflowing pipeline of really interesting research activity that's coming out of the universities," Cassidy said. "We're going to put some more tools in place to assist in translation and commercialization of those discoveries."
GRA is broadly focused; Cassidy identified Internet security and energy management products as ones in the pipeline that have him excited. But biomedical research plays a critical role in the state's economic development plans, and more than half of GRA's portfolio involves biomedical research.
Looking back, Cassidy says that the Emory Vaccine Center has been a shining example of how GRA proves the power of business, government and academia working together. In the mid-1990s, GRA and Emory University lured to the state noted vaccine researcher Rafi Ahmed, PhD, as part of GRA's Eminent Scholars recruitment program. Ahmed launched the Emory Vaccine Center in 1996, which has since secured more than $260 million in research funding. One of the discoveries at the Emory Vaccine Center led to the creation of GeoVax, which employs 14 people in suburban Atlanta and reported nearly $5 million in revenues in 2011.
Policy perspective from Washington is a key factor for GRA's membership with Research!America.
"We derive tremendous value through our membership in Research!America. Insight into what's going on at the federal level is giving us a better idea of how to shape our own strategies and policies, and Research!America's opinion polls have been particularly informative," Cassidy said. "GRA was very active as one of the sites within the global health initiative and really enjoyed working with the Research!America team. We are much more tuned in to Washington in ways that we probably wouldn't have been on our own."
To learn more, visit www.gra.org.
The Children's Hospital of Philadelphia was founded in 1855, but it took nearly seven decades for research to become part of the institution's mission. Growing from a one-room laboratory in 1922, Children's Hospital has made incredible progress since: the basis of the foundation of the Society for Pediatric Research, the country's first pediatric research department, and numerous scientific breakthroughs and vaccine discoveries.
Children's Hospital's 10 Centers of Emphasis encompass seemingly disparate research areas, but all contribute to the greater strategic goals of the hospital's research efforts.
"Our interests are embedded in those Centers of Emphasis," said Philip R. Johnson, MD, director of the hospital's research institute as well as its chief scientific officer and an executive vice president. The centers that Johnson oversees are dedicated to applied genomics, autism, biomedical informatics, cellular and molecular therapies, pediatric cancer, developmental biology and pediatric disorders, injury research and prevention, mitochondrial and epigenomic medicine, pediatric clinical effectiveness, and even health care policy.
The hospital also supports Research Affinity Groups, which Johnson likened to a "grassroots" effort among researchers to explore topics of interest. The groups, designed to encourage interdisciplinary approaches to child health and development, cover areas different from the Centers of Emphasis.
Johnson's own research centers on finding a vaccine for HIV, but not in the traditional way a vaccine works. Instead, viruses are used to carry genes that code for HIV antibodies. When injected into muscle, the muscle takes over production of those antibodies which can then defeat HIV. Johnson said this concept is nearing a clinical trial in humans. The hope, then, is that such an approach might be useful in developing similar vaccines for other diseases and conditions as well.
Research!America's efforts to educate the public and policy makers are a big reason why Children's Hospital is a member, Johnson said.
"It's amazing the amount of misunderstanding about research that exists in the general population," Johnson said. "... They understand it's important, but they don't understand the mechanics of it, the politics and the support that's required.
"Research!America does a better job of that than anybody else, and that's why we're very supportive of the activities."
For more, visit www.research.chop.edu.
Baxter International traces its roots to 1931, when it became the first manufacturer of commercially prepared intravenous solutions. Only four years later, Baxter began research and development activities. More than 80 years later, Baxter is noted for its breakthroughs in kidney dialysis, hemophilia, vaccines and a host of other areas. In 2011, its worldwide sales neared $14 billion, and it boasted an R&D budget of $946 million.
The academic focus of Norbert Riedel, PhD, was biochemistry. But as Baxter's corporate vice president and chief science and innovation officer, the demands of his job spread far beyond that one subject. The company's portfolio is vast, incorporating pharmaceuticals, medical devices and biotechnology. Such diversity is a defining characteristic, Baxter's website notes-and it gives Riedel much to think about each day.
"That is part of the very reason why I like this job very much," Riedel said. On a day-to-day basis, he added, he makes use of both the specialized staff that reports to him and nearby academic connections, which helps him understand technological advances in academia. Beyond that, he added, a general sense of the science and technology world, as well as a curious mind, are also helpful.
Riedel is particularly excited about two areas: a late-stage clinical trial for a promising Alzheimer's disease therapy, as well as a therapy in which patients' own stem cells are injected into their heart muscle as a way of treating heart disease. Another area of potential is a cancer therapy that came from Baxter's early-stage R&D group.
Baxter's membership with Research!America, Riedel said, is not only a way to support American competitiveness but also a way to keep the spotlight on challenges whose solutions lie in research.
"In my view, the key global challenges that we have as a global community all depend on scientific discovery and technology to find effective solutions and to find effective ways of tackling these challenges," he said. "And I believe the United States has been a leader in this for decades and must remain a leader. And therefore Research!America emphasizes the need for adequate funding for adequate education in science and all the things that literally have made this nation a great nation but also are areas in which we are beginning to lose our competitive edge."
To learn more, visit www.baxter.com.
Tracing its roots to 1914, the Ohio State University College of Nursing became part of OSU in 1922, its own distinct school within OSU in 1928 and an autonomous college in 1984. Today, the college has a $14.1 million budget to support more than 120 faculty and staff and 1,487 students. The college's mission is to transform health and transform lives through innovative academic programs, cutting-edge research that improves outcomes and evidence-based clinical practice.
Bernadette Mazurek Melnyk, PhD, RN, is the dean of the College of Nursing, but that's hardly her only role at Ohio State. She's also the university's chief wellness officer and its associate vice president for health promotion. All of it adds up to a busy woman.
"Every day is very exciting, and I never have the opportunity to be bored," Melnyk said with a laugh.
She is a big believer in the evidence-based practice that shows up in the college's curriculum. "We start from the foundation, from the day [students] enter their programs," Melnyk said. In her role as the university's chief wellness officer, she spearheads the implementation of evidence-based health and wellness initiatives across the university. But, she said, unless these best practices are actually implemented in the clinical or real-world setting, they are of little use. Ensuring that happens requires continuous effort and reinforcement.
Melnyk is also concerned about what she sees regarding the lack of measures included in research that most directly affect health outcomes and the bottom line. For instance, she said, her own research on parents of low birth weight premature babies was more than 20 years in the making before it was implemented in neonatal intensive care units across the country-and only then because her trials demonstrated that babies could spend an average of four fewer days in the hospital, eight days less with preterms under 32 weeks.
"So that has huge cost implications," Melnyk said.
As for the future, her vision goes far beyond the OSU campus: Melnyk wants to extend the goal of having "the healthiest university on the globe" beyond the campus to the community of Columbus and the state of Ohio, and will track important outcome data to demonstrate how and when that happens.
Research!America's advocacy is a critical reason why the College of Nursing is a member.
"The advocacy that you do, the connections that you have to garner more funding and resources for us, particularly in academia, is super important," Melnyk said.
To learn more, visit http://nursing.osu.edu.
Rice University has multiple centers that focus on biomedical research of one kind or another. Another center, the James A. Baker III Institute for Public Policy, studies the area that its name implies; one of those areas is the intersection of public policy and science and technology. The program aims to increase scientific engagement with the public and researches the role of medicine and stem cell research in public policy.
After a stint in Washington as director of the National Science Foundation and the White House Office of Science and Technology Policy, Neal Lane, PhD, returned to Rice as a faculty member in the Baker Institute in 2001. The institute already had strengths in energy and foreign affairs but was looking for expertise in science and technology policy. As the program grew, Lane gained a trusted deputy in 2003: Kirstin R. W. Matthews, PhD.
Today, the two co-direct the science and technology program of the Baker Institute.
"Our mission that we decided on, when we put this program together, was really to kind of put together scientists with policy scholars and policy makers," Matthews said. "The whole overall goal is while not everything gets to be decided on science, but at least they have the science-the right science-in front them when making any decisions."
That mission manifests itself not only in policy research but in programs within the science and technology program: The Civic Scientist Program brings well-known lecturers to campus, highlights contributions of scientists and engineers who have impacted public policy, and brings scientists to local schoolchildren to talk about careers in science. There's also an initiative with the M.D. Anderson Cancer Center that examines medicine and public policy issues, and the institute's work on stem cell research policy has helped inform policy makers and the public in Texas and across the country.
"When Kirstin came aboard, she brought an in-depth understanding of [stem cell] science and the potential therapeutic potential, and [she] also knew a lot about the policy implications," Lane said. "There was a lot going on in Texas in those early years after Kirstin came here. And we worked with people in Texas and nationally on pending legislation."
To learn more, visit www.bakerinstitute.org/programs/scitech.
RTI International was established in 1958 as the nonprofit Research Triangle Institute, the founding tenant of North Carolina's Research Triangle Park. RTI was founded as part of a larger effort to harness the intellectual capital of the area's three major universities-North Carolina State University, University of North Carolina and Duke University. Since that time, RTI has grown from a handful of dedicated scientists into an international organization of more than 2,800 individuals conducting research and development projects in 40 countries throughout the world.
RTI's activities both mirror and support national priorities and policies as well as diverse commercial, industrial and academic endeavors. Health research is RTI's largest single field of study, encompassing research that ranges from studies of the human genome and the development of new drug compounds to national surveys of health behaviors and the implementation of global health programs.
"Our research is driven by our mission to improve the human condition," said Wayne Holden, PhD, RTI International president and chief executive officer. "We work to address many of the world's complex problems in a broad range of areas from science to implementation."
A major aspect of RTI's work is conducting economic and social policy research to help inform and positively benefit public policy. RTI researchers have conducted numerous studies to help federal officials determine which programs work, which are most cost-effective and which are ineffective.
"As an organization that conducts a wide range of federally funded research in the health sector, we value those organizations such as Research!America that advocate for federal research funding," Holden said. "They play a vital role in supporting our nation's research agenda and helping communicate the value of our nation's investment in research."
For more information, visit www.rti.org.